These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32124443)

  • 21. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
    N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
    Nishihori T; Baz R
    Expert Opin Drug Saf; 2020 Feb; 19(2):113-115. PubMed ID: 31910353
    [No Abstract]   [Full Text] [Related]  

  • 23. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
    Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D; Berdeja JG; Reece D; White D; Lentzsch S; Gasparetto C; Huff CA; Jagannath S; Baz R; Nooka AK; Richter J; Abonour R; Parker TL; Yee AJ; Moreau P; Lonial S; Tuchman S; Weisel KC; Mohty M; Choquet S; Unger TJ; Li K; Chai Y; Li L; Shah J; Shacham S; Kauffman MG; Dimopoulos MA
    Leukemia; 2020 Sep; 34(9):2430-2440. PubMed ID: 32094461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials.
    Abid H; Wu JF; Abid MB
    Eur J Cancer; 2021 Sep; 154():7-10. PubMed ID: 34217910
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
    Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
    J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 'comeback' of Selinexor: From toxic to tolerable.
    Hashmi H; Green K
    Curr Probl Cancer; 2022 Feb; 46(1):100789. PubMed ID: 34479762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
    Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
    Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment].
    Croizier C; Van de Wyngaert Z
    Bull Cancer; 2022 Feb; 109(2):113-114. PubMed ID: 35063182
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.
    Mi JQ; Zhao W; Jing H; Jin J; Chen SJ
    Eur J Cancer; 2023 Jul; 188():108-110. PubMed ID: 37229834
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.
    Li H; Yin L; Wang Y; Wang X; Shi M; Cao J; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
    Bone Marrow Transplant; 2020 Nov; 55(11):2215-2218. PubMed ID: 32388534
    [No Abstract]   [Full Text] [Related]  

  • 31. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
    Restrepo P; Bhalla S; Ghodke-Puranik Y; Aleman A; Leshchenko V; Melnekoff DT; Agte S; Jiang J; Madduri D; Richter J; Richard S; Chari A; Cho HJ; Jagannath S; Walker CJ; Landesman Y; Laganà A; Parekh S
    JCO Precis Oncol; 2022 Jun; 6():e2200147. PubMed ID: 35704796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selinexor-dexamethasone for refractory multiple myeloma.
    Stirrups R
    Lancet Oncol; 2019 Oct; 20(10):e560. PubMed ID: 31477451
    [No Abstract]   [Full Text] [Related]  

  • 33. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
    Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
    Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
    Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
    Front Immunol; 2019; 10():1613. PubMed ID: 31379824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
    Rosebeck S; Alonge MM; Kandarpa M; Mayampurath A; Volchenboum SL; Jasielec J; Dytfeld D; Maxwell SP; Kraftson SJ; McCauley D; Shacham S; Kauffman M; Jakubowiak AJ
    Mol Cancer Ther; 2016 Jan; 15(1):60-71. PubMed ID: 26637366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions.
    Haslam A; Gill J; Prasad V
    Mayo Clin Proc; 2020 Feb; 95(2):424-426. PubMed ID: 32029095
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy.
    Jin A; Feng J; Wang Z; Jiang L; Hu Y; Zhao K; Huang H
    Bone Marrow Transplant; 2019 Jul; 54(7):969-972. PubMed ID: 30563981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown
    Wahba A; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
    Mol Cancer Ther; 2018 Aug; 17(8):1717-1726. PubMed ID: 29866745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Bobillo S; Abrisqueta P; Carpio C; Raheja P; Castellví J; Crespo M; Bosch F
    Haematologica; 2018 Feb; 103(2):e92-e93. PubMed ID: 29242296
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.
    Frey N; Porter D
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):e123-e127. PubMed ID: 30586620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.